Developing long-lasting treatments for HIV prevention and therapy
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10877335
This study is testing new ways to deliver HIV medications that last for weeks, like special rings or tiny crystals, to make it easier for people to stay on track with their treatment and help prevent HIV transmission.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10877335 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative long-acting formulations of antiretrovirals that can be administered over several weeks, either through nanocrystal-based formulations or intravaginal rings. By improving patient compliance and reducing the need for daily dosing, these formulations aim to enhance the effectiveness of HIV prevention and treatment. The research utilizes animal models to evaluate the safety and efficacy of these new delivery systems, with the goal of achieving sustained viral suppression and protection from HIV transmission.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for HIV infection or those currently undergoing HIV treatment.
Not a fit: Patients who are not at risk for HIV or those who are already effectively managing their HIV with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and convenient options for HIV prevention and treatment.
How similar studies have performed: Previous research has shown promise in developing long-acting formulations for HIV prevention and treatment, indicating a potential for success in this area.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARCIA-MARTINEZ, J. VICTOR — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: GARCIA-MARTINEZ, J. VICTOR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.